Quantcast

Latest Prostate cancer Stories

2014-03-06 08:30:07

AVEED offers distinct dosing schedule to increase testosterone levels in hypogonadal men, and underscores Endo's strategy and commitment to addressing health issues facing men DUBLIN, March 6, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that its operating company Endo Pharmaceuticals Inc. received U.S. Food and Drug Administration (FDA) approval of AVEED(TM) (testosterone undecanoate) injection for the treatment of adult men with hypogonadism...

2014-03-05 23:25:20

Diabetic patients who develop bladder cancer after taking the drug Actos (pioglitazone) tend to have about the same number of Stage I, II, and III cancers as surgical patients who never used Actos. Raleigh, NC (PRWEB) March 05, 2014 A new published study of patients who had their bladders removed because of cancer suggests that the drug Actos may not have much effect on the growth and extent of cancer. As Cancer Monthly reports, the study, published in BMC Urology, examined the cases of...

2014-03-05 11:06:28

Researchers have discovered a link between prostate cancer aggressiveness and the accumulation of a compound produced when cholesterol is metabolized in cells, findings that could bring new diagnostic and treatment methods. Findings also suggest that a class of drugs previously developed to treat atherosclerosis might be repurposed for treatment of advanced prostate cancer. The research showed depletion of the compound cholesteryl ester significantly reduced prostate cancer cell...

2014-03-05 11:01:37

Johns Hopkins researchers identify set of genes that can be turned back on and potentially allow for more effective treatment Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment. Immune therapy for ovarian, breast and colorectal cancer — treatments that encourage the...

2014-03-05 08:29:16

Lung, Prostate, and Brain Cancer Patients Receive Edge Radiosurgery at Champalimaud Center for the Unknown LISBON, Portugal, March 5, 2014 /PRNewswire/ -- Doctors at the Champalimaud Center for the Unknown here have performed the world's first cancer treatments using the new advanced Edge(TM) radiosurgery system from Varian Medical Systems (NYSE: VAR). This fast, precise and non-invasive alternative to conventional surgery was used to treat several patients with lung, prostate and...

BPA Raises Prostate Cancer Risk
2014-03-05 08:30:00

Rebekah Eliason for redOrbit.com - Your Universe Online A new study from the Cincinnati Cancer Center discovered that if the chemical bisphenol A (BPA) is found in men’s urine it may be a marker for prostate cancer. According to the researchers, even low levels of exposure to BPA can cause changes within non-malignant and malignant prostate cells. These findings provide the first evidence that urinary levels of BPA could predict prostate cancer. Also, the researchers discovered...

2014-03-04 12:26:37

Doug Kammerer Chosen as First LUNGevity Hero WASHINGTON, March 4, 2014 /PRNewswire-USNewswire/ -- The LUNGevity Foundation announces the LUNGevity Heroes program, a monthly honor recognizing individuals or organizations whose advocacy or research is making a difference in the fight against lung cancer. The top cancer killer in the United States, lung cancer, can affect anyone, regardless of smoking history, gender, or ethnicity, but remains underfunded and overlooked. LUNGevity Heroes...

2014-03-04 12:25:43

Urology Device Market Set to Reach Over $2.6 Billion by 2022, According to Findings from Decision Resources Group BURLINGTON, Mass., March 4, 2014 /PRNewswire/ -- Decision Resources Group finds that the United States market for urological devices will expand to over $2.6 billion by 2022. While some formerly high-growth segments, including vaginal slings, benign prostatic hyperplasia (BPH) treatment devices and prostate cancer treatment devices, declined in 2013, various factors will...

2014-03-04 08:31:51

SAN DIEGO, March 4, 2014 /PRNewswire/ -- GenomeDx Biosciences announced that it will present today at the 34(th) Annual Cowen and Company Healthcare Conference at 4:30 p.m. ET in Boston, Massachusetts. Doug Dolginow, M.D., CEO of GenomeDx, will provide a progress update on the commercialization of its Decipher® test and an overview of the Company's product pipeline in urology. About Decipher® The Decipher Prostate Cancer Classifier is a genomic test that directly measures the...

2014-03-03 16:25:26

$250,000 to support immuno-oncology learning resources WASHINGTON, March 3, 2014 /PRNewswire-USNewswire/ -- LUNGevity Foundation is honored to announce a grant of $250,000 from Bristol-Myers Squibb for the development of educational materials on immuno-oncology. Progress in understanding lung cancer and treatment approaches has accelerated dramatically in the past several years after many slow decades. While no immunotherapeutic drugs are currently approved for lung cancer, this new area of...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related